1bnl › Citations

Zinc-dependent dimers observed in crystals of human endostatin.

Ding YH, Javaherian K, Lo KM, Chopra R, Boehm T, Lanciotti J, Harris BA, Li Y, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley DC
Proc Natl Acad Sci U S A 95 10443-8 (1998)
Cited: 79 times
EuropePMC logo PMID: 9724722

Abstract

The crystal structure of human endostatin reveals a zinc-binding site. Atomic absorption spectroscopy indicates that zinc is a constituent of both human and murine endostatin in solution. The human endostatin zinc site is formed by three histidines at the N terminus, residues 1, 3, and, 11, and an aspartic acid at residue 76. The N-terminal loop ordered around the zinc makes a dimeric contact in human endostatin crystals. The location of the zinc site at the amino terminus, immediately adjacent to the precursor cleavage site, suggests the possibility that the zinc may be involved in activation of the antiangiogenic activity following cleavage from the inactive collagen XVIII precursor or in the cleavage process itself.

Articles - 1bnl mentioned but not cited (8)

  1. Zinc-dependent dimers observed in crystals of human endostatin. Ding YH, Javaherian K, Lo KM, Chopra R, Boehm T, Lanciotti J, Harris BA, Li Y, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley DC. Proc. Natl. Acad. Sci. U.S.A. 95 10443-10448 (1998)
  2. Molecular interplay between endostatin, integrins, and heparan sulfate. Faye C, Moreau C, Chautard E, Jetne R, Fukai N, Ruggiero F, Humphries MJ, Olsen BR, Ricard-Blum S. J. Biol. Chem. 284 22029-22040 (2009)
  3. Calculation of accurate small angle X-ray scattering curves from coarse-grained protein models. Stovgaard K, Andreetta C, Ferkinghoff-Borg J, Hamelryck T. BMC Bioinformatics 11 429 (2010)
  4. Novel pathogenic mutations and skin biopsy analysis in Knobloch syndrome. Suzuki O, Kague E, Bagatini K, Tu H, Heljasvaara R, Carvalhaes L, Gava E, de Oliveira G, Godoi P, Oliva G, Kitten G, Pihlajaniemi T, Passos-Bueno MR. Mol. Vis. 15 801-809 (2009)
  5. Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Lee JH, Isayeva T, Larson MR, Sawant A, Cha HR, Chanda D, Chesnokov IN, Ponnazhagan S. Proc. Natl. Acad. Sci. U.S.A. 112 1392-1397 (2015)
  6. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  7. Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli. Setrerrahmane S, Yu J, Hao J, Zheng H, Xu H. Drug Des Devel Ther 11 3207-3220 (2017)
  8. Phylogeny of Echinoderm Hemoglobins. Christensen AB, Herman JL, Elphick MR, Kober KM, Janies D, Linchangco G, Semmens DC, Bailly X, Vinogradov SN, Hoogewijs D. PLoS ONE 10 e0129668 (2015)


Reviews citing this publication (20)

  1. Angiogenesis. Folkman J. Annu. Rev. Med. 57 1-18 (2006)
  2. New functional roles for non-collagenous domains of basement membrane collagens. Ortega N, Werb Z. J. Cell. Sci. 115 4201-4214 (2002)
  3. The collagen superfamily: from the extracellular matrix to the cell membrane. Ricard-Blum S, Ruggiero F. Pathol. Biol. 53 430-442 (2005)
  4. Domain structure and organisation in extracellular matrix proteins. Hohenester E, Engel J. Matrix Biol. 21 115-128 (2002)
  5. Collagen XVIII/endostatin structure and functional role in angiogenesis. Zatterstrom UK, Felbor U, Fukai N, Olsen BR. Cell Struct. Funct. 25 97-101 (2000)
  6. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Ricard-Blum S, Salza R. Exp. Dermatol. 23 457-463 (2014)
  7. Anti-angiogenic treatment strategies for malignant brain tumors. Kirsch M, Schackert G, Black PM. J. Neurooncol. 50 149-163 (2000)
  8. Unraveling the mysteries of endostatin. Fu Y, Tang H, Huang Y, Song N, Luo Y. IUBMB Life 61 613-626 (2009)
  9. Endostatin action and intracellular signaling: beta-catenin as a potential target? Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Cancer Lett. 196 1-12 (2003)
  10. Control of melanoma progression by various matrikines from basement membrane macromolecules. Pasco S, Ramont L, Maquart FX, Monboisse JC. Crit. Rev. Oncol. Hematol. 49 221-233 (2004)
  11. Endostatin: current concepts about its biological role and mechanisms of action. Digtyar AV, Pozdnyakova NV, Feldman NB, Lutsenko SV, Severin SE. Biochemistry Mosc. 72 235-246 (2007)
  12. Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers. Poluzzi C, Iozzo RV, Schaefer L. Adv. Drug Deliv. Rev. 97 156-173 (2016)
  13. Matrikines and the lungs. Burgess JK, Weckmann M. Pharmacol. Ther. 134 317-337 (2012)
  14. Structural basis for the functions of endogenous angiogenesis inhibitors. Grant MA, Kalluri R. Cold Spring Harb. Symp. Quant. Biol. 70 399-410 (2005)
  15. Cellular actions and signaling by endostatin. Ramchandran R, Karumanchi SA, Hanai J, Alper SL, Sukhatme VP. Crit. Rev. Eukaryot. Gene Expr. 12 175-191 (2002)
  16. Endostatin: a promising drug for antiangiogenic therapy. Cirri L, Donnini S, Morbidelli L, Chiarugi P, Ziche M, Ledda F. Int. J. Biol. Markers 14 263-267 (1999)
  17. Delivery of endostatin in experimental cancer therapy. Sorensen DR, Read TA. Int J Exp Pathol 83 265-274 (2002)
  18. The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering. Mohajeri A, Sanaei S, Kiafar F, Fattahi A, Khalili M, Zarghami N. Adv Pharm Bull 7 21-34 (2017)
  19. Collagen XVIII in tissue homeostasis and dysregulation - Lessons learned from model organisms and human patients. Heljasvaara R, Aikio M, Ruotsalainen H, Pihlajaniemi T. Matrix Biol. 57-58 55-75 (2017)
  20. Biological aspects in controlling angiogenesis: current progress. Akbarian M, Bertassoni LE, Tayebi L. Cell Mol Life Sci 79 349 (2022)

Articles citing this publication (51)

  1. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. J. Clin. Oncol. 21 223-231 (2003)
  2. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. J. Mol. Biol. 301 1179-1190 (2000)
  3. Cloning, expression, and in vitro activity of human endostatin. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Biochem. Biophys. Res. Commun. 258 345-352 (1999)
  4. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. Miosge N, Sasaki T, Timpl R. FASEB J. 13 1743-1750 (1999)
  5. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, McCrae KR. FASEB J. 14 2589-2600 (2000)
  6. Addresses Is angiogenesis an organizing principle in biology and medicine? Folkman J. J. Pediatr. Surg. 42 1-11 (2007)
  7. Zinc-binding of endostatin is essential for its antiangiogenic activity. Boehm T, O'reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J. Biochem. Biophys. Res. Commun. 252 190-194 (1998)
  8. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. Kuo CJ, LaMontagne KR, Garcia-Cardeña G, Ackley BD, Kalman D, Park S, Christofferson R, Kamihara J, Ding YH, Lo KM, Gillies S, Folkman J, Mulligan RC, Javaherian K. J. Cell Biol. 152 1233-1246 (2001)
  9. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Chen CT, Lin J, Li Q, Phipps SS, Jakubczak JL, Stewart DA, Skripchenko Y, Forry-Schaudies S, Wood J, Schnell C, Hallenbeck PL. Hum. Gene Ther. 11 1983-1996 (2000)
  10. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D'Amato RJ. Fertil. Steril. 85 71-77 (2006)
  11. The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells. Song N, Ding Y, Zhuo W, He T, Fu Z, Chen Y, Song X, Fu Y, Luo Y. Angiogenesis 15 697-711 (2012)
  12. Endostatin therapy reveals a U-shaped curve for antitumor activity. Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J, Javaherian K. Cancer Gene Ther. 13 619-627 (2006)
  13. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP, Pang YP, McCrae KR. Proc. Natl. Acad. Sci. U.S.A. 99 12224-12229 (2002)
  14. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Cattaneo MG, Pola S, Francescato P, Chillemi F, Vicentini LM. Exp. Cell Res. 283 230-236 (2003)
  15. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Curr Oncol Rep 3 131-140 (2001)
  16. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Chang Z, Choon A, Friedl A. Am. J. Pathol. 155 71-76 (1999)
  17. A survey of left-handed helices in protein structures. Novotny M, Kleywegt GJ. J. Mol. Biol. 347 231-241 (2005)
  18. Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis. Zeng X, Chen J, Miller YI, Javaherian K, Moulton KS. J. Lipid Res. 46 1849-1859 (2005)
  19. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. Kranenburg O, Kroon-Batenburg LM, Reijerkerk A, Wu YP, Voest EE, Gebbink MF. FEBS Lett. 539 149-155 (2003)
  20. Aberrant neuronal and paracellular deposition of endostatin in brains of patients with Alzheimer's disease. Deininger MH, Fimmen BA, Thal DR, Schluesener HJ, Meyermann R. J. Neurosci. 22 10621-10626 (2002)
  21. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A, Combaret V, Favrot M, Leboulch P, Bachelot T. J. Neurooncol. 51 11-18 (2001)
  22. Intrinsic disorder of the extracellular matrix. Peysselon F, Xue B, Uversky VN, Ricard-Blum S. Mol Biosyst 7 3353-3365 (2011)
  23. Crystal structure of YbaK protein from Haemophilus influenzae (HI1434) at 1.8 A resolution: functional implications. Zhang H, Huang K, Li Z, Banerjei L, Fisher KE, Grishin NV, Eisenstein E, Herzberg O. Proteins 40 86-97 (2000)
  24. Expression of soluble, biologically active recombinant human endostatin in Escherichia coli. Xu HM, Zhang GY, Ji XD, Cao L, Shu L, Hua ZC. Protein Expr. Purif. 41 252-258 (2005)
  25. Contributions of Zn(II)-binding to the structural stability of endostatin. Han Q, Fu Y, Zhou H, He Y, Luo Y. FEBS Lett. 581 3027-3032 (2007)
  26. Bioinorganic aspects of angiogenesis. D'Andrea LD, Romanelli A, Di Stasi R, Pedone C. Dalton Trans 39 7625-7636 (2010)
  27. Extended interaction network of procollagen C-proteinase enhancer-1 in the extracellular matrix. Salza R, Peysselon F, Chautard E, Faye C, Moschcovich L, Weiss T, Perrin-Cocon L, Lotteau V, Kessler E, Ricard-Blum S. Biochem. J. 457 137-149 (2014)
  28. N-terminal modification increases the stability of the recombinant human endostatin in vitro. Jiang LP, Zou C, Yuan X, Luo W, Wen Y, Chen Y. Biotechnol. Appl. Biochem. 54 113-120 (2009)
  29. Deficiency of disulfide bonds facilitating fibrillogenesis of endostatin. He Y, Zhou H, Tang H, Luo Y. J Biol Chem 281 1048-1057 (2006)
  30. Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. Blackhall FH, Merry CL, Lyon M, Jayson GC, Folkman J, Javaherian K, Gallagher JT. Biochem. J. 375 131-139 (2003)
  31. Modern diets and diseases: NO-zinc balance. Under Th1, zinc and nitrogen monoxide (NO) collectively protect against viruses, AIDS, autoimmunity, diabetes, allergies, asthma, infectious diseases, atherosclerosis and cancer. Sprietsma JE. Med. Hypotheses 53 6-16 (1999)
  32. Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway. Deininger MH, Wybranietz WA, Graepler FT, Lauer UM, Meyermann R, Schluesener HJ. FASEB J. 17 1267-1276 (2003)
  33. Variable zinc coordination in endostatin. Hohenester E, Sasaki T, Mann K, Timpl R. J. Mol. Biol. 297 1-6 (2000)
  34. Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles. Javaherian K, Lee TY, Tjin Tham Sjin RM, Parris GE, Hlatky L. Dose Response 9 369-376 (2011)
  35. Accumulation of endostatin/collagenXVIII in brains of patients who died with cerebral malaria. Deininger MH, Fimmen B, Kremsner PG, Meyermann R, Schluesener HJ. J. Neuroimmunol. 131 216-221 (2002)
  36. A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody. Farrugia W, Scott AM, Ramsland PA. PLoS ONE 4 e7777 (2009)
  37. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis. Jiang WG, Lu XA, Shang BY, Fu Y, Zhang SH, Zhou D, Li L, Li Y, Luo Y, Zhen YS. BMC Cancer 13 479 (2013)
  38. Detection and characterization of an acid-induced folding intermediate of endostatin. Wu X, Huang J, Chang G, Luo Y. Biochem. Biophys. Res. Commun. 320 973-978 (2004)
  39. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. Grossman R, Tyler B, Hwang L, Zadnik P, Lal B, Javaherian K, Brem H. J. Neurosurg. 115 1139-1146 (2011)
  40. Sulfate stabilizes the folding intermediate more than the native structure of endostatin. Fu Y, Wu X, Han Q, Liang Y, He Y, Luo Y. Arch. Biochem. Biophys. 471 232-239 (2008)
  41. Endostatin phenylalanines 31 and 34 define a receptor binding site. Stahl S, Gaetzner S, Mueller TD, Felbor U. Genes Cells 10 929-939 (2005)
  42. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study. Torres PH, Sousa GL, Pascutti PG. Proteins 79 2684-2692 (2011)
  43. Anti-angiogenic treatment of human cancer: pitfalls and promises. Westphal JR, Ruiter DJ, De Waal RM. Int. J. Cancer 86 870-873 (2000)
  44. Tunicate cytostatic factor TC14-3 induces a polycomb group gene and histone modification through Ca(2+) binding and protein dimerization. Kawamura K, Takakura K, Mori D, Ikeda K, Nakamura A, Suzuki T. BMC Cell Biol. 13 3 (2012)
  45. Nuclear-translocated endostatin downregulates hypoxia inducible factor-1α activation through interfering with Zn(II) homeostasis. Guo L, Chen Y, He T, Qi F, Liu G, Fu Y, Rao C, Wang J, Luo Y. Mol Med Rep 11 3473-3480 (2015)
  46. Zinc supplementation protects human endostatin Fc fusion against proteolytic degradation during cell culture. Hao G, Dawson J, Lee G, Longley R. Protein Expr. Purif. 93 18-22 (2014)
  47. A molecular dynamics study of human endostatin and its synthetic fragments with antiangiogenic properties. Pieraccini S, Sironi M, Francescato P, Speranza G, Vicentini LM, Manitto P. Phys Chem Chem Phys 8 3066-3071 (2006)
  48. An extracellular proteasome releases endostatin from human collagen XVIII. Reiss-Pistilli ML, Schuppan D, Barroso MM, Assunção-Miranda I, Farias S, Lery L, Bauer M, Juliano L, Juliano MA, Coelho-Sampaio T. Angiogenesis 20 125-137 (2017)
  49. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights. Chamani R, Asghari SM, Alizadeh AM, Eskandari S, Mansouri K, Khodarahmi R, Taghdir M, Heidari Z, Gorji A, Aliakbar A, Ranjbar B, Khajeh K. Vascul. Pharmacol. 72 73-82 (2015)
  50. A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycans. Moriyama M, Toba K, Hanawa H, Kato K, Yanagawa T, Takayama T, Ozawa T, Kobayashi H, Higuchi M, Saito H, Aizawa Y. Drug Deliv 19 202-207 (2012)
  51. The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated. Huhn AJ, Parsonage D, Horita DA, Torti FM, Torti SV, Hollis T. Protein Sci. 23 1013-1022 (2014)


Quick links